Study wrapper · #1085
Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.
Kopp KL, Lamberth K, Schelde O, et al. Pharmaceutical research. 2026.
DOI: 10.1007/s11095-026-04146-9PubMed: 42533250
Editor's note
This in vitro analysis is directly relevant to readers considering compounded or follow-on semaglutide, showing measurable impurity and immunogenicity differences versus originator products. The work characterizes laboratory potential rather than confirmed clinical immune reactions, so the real-world consequence remains to be established. It reinforces quality and sourcing concerns around compounded peptide products.
Plain-language abstract
Laboratory testing found that compounded and follow-on semaglutide and liraglutide products carried distinct impurity profiles and greater potential immunogenicity than the original branded products. Compounded semaglutide also showed reduced stability when exposed to light.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026